top of page

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Janssen has announced results from a pivotal Phase III study evaluating subcutaneous sirukumab (CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).


Click on this link for more information.

source: http://www.europeanpharmaceuticalreview.com/41593/news/industry-news/sirukumab-ra-study/


#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page